Full-Time

Strategy & Commercial Manager

Updated on 9/3/2026

Eucalyptus

Eucalyptus

501-1,000 employees

Global telehealth platform offering digital clinics

No salary listed

London, UK

In Person

Remote up to 3 weeks per year.

Category
Business & Strategy (1)
Required Skills
Claude
Data Analysis

Get referred to Eucalyptus

See people who can refer or advise you

Requirements
  • You have at least 6+ years experience working in a high-pressure environment such as consulting (MBB preferred), investment banking, or as an operator in a recent high-growth startup.
  • Commercial & financial modelling: You can build a commercial model from scratch, make your assumptions explicit, and defend them across market sizing, unit economics (CAC, LTV, payback) and deal structures.
  • Business understanding & due diligence: You quickly grasp what makes a market or partnership successful for Eucalyptus, what the unit economics depend on, and how options compare. You use that understanding to frame your research and produce a clear, structured point of view to support a go/no-go decision.
  • AI & Data: You're comfortable getting your own answers from data and know how to make AI work for you. You're genuinely strong with Claude, not just prompting it for first drafts, but using it to automate access to information, stress-test arguments, and build repeatable workflows. You see it as leverage on your thinking, never a replacement for it. The ability to self serve on Sigma will also be highly valued.
  • Negotiation: You've had real commercial conversations with partners, suppliers and pharma companies, and moved them forward.
  • Project management: You've run complex cross-functional workstreams with real accountability.
  • Communication: You write tight investment theses and clear slide decks.
  • Founder mindset: You operate like a founder and enjoy the hustle of getting things done. You are an example of resilience and ownership — when something breaks you fix it, you don't wait for others.
Responsibilities
  • Operating Countries: set up and pull the right levers to win in every country. You will help set up strategy and own the commercial performance of our live markets (Canada, Germany and Japan today, with more to come). That means understanding what drives each market's P&L, running experiments across the funnel, placing data-driven bets, and partnering with local teams to execute them. You’ll work closely with GMs to set up joint OKRs to execute the strategy and win each market.
  • Global Pharma & Strategic Partnerships: strategise with our most important commercial relationships globally. This covers our big-pharma partners (e.g. Novo Nordisk, Eli Lilly) alongside strategic partnerships and corporate development (M&A, supply and distribution). You'll help set strategies (medication launches), structure and negotiate commercial deals (rebates, co-funding and demand-generation), build the models that underpin them and help execute long term value drivers for the business.
  • Group Strategy: high-value, ad-hoc projects that drive the International business. Think Special Situations / Biz Ops. One month it's acquiring a business or unlocking regs for growth, the next a pricing overhaul or an org-design question. You’ll be looking ahead, thinking through the bets you need to make to always be one step ahead of the competition and win market share. You scope the problem, build the analysis, drive to a clear recommendation, and often own the execution that follows.

Eucalyptus.vc runs digital healthcare clinics as a global telehealth service focused on patient-first care. Patients connect with certified practitioners for remote consultations, treatments, and ongoing care entirely through the online platform. The service provides end-to-end care in one digital ecosystem, from initial visit to follow-up, with revenue from fees for these clinical services. The company aims to make safe, effective care accessible worldwide by leveraging its global team of over 400 professionals to operate the clinics.

Company Size

501-1,000

Company Stage

Acquired

Total Funding

$139.7M

Headquarters

Sydney, Australia

Founded

2019

Get referred to Eucalyptus

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • Eucalyptus served 850,000 customers by May 2026, proving scale before acquisition.
  • The August 31, 2026 Australian launch extends 24/7 access and broader treatment combinations.
  • Tim Doyle now runs Hims international, keeping Eucalyptus expertise inside a larger platform.

What critics are saying

  • Hims filed the Pilot-to-Hims rebrand on August 31, 2026, erasing Eucalyptus identity.
  • The FTC sued Hims on July 29, 2026, intensifying telehealth compliance scrutiny.
  • Australia lacks dedicated telehealth clinic regulation, inviting crackdowns that can disrupt Eucalyptus operations.

What makes Eucalyptus unique

  • Eucalyptus built local telehealth brands across Australia, UK, Germany, Japan, and Canada.
  • Its clinical model pairs local providers with direct-to-consumer digital pathways.
  • Hims acquired Eucalyptus on June 2, 2026, validating its operational playbook.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Employee Stock Purchase Plan

Flexible Work Hours

Hybrid Work Options

Wellness Program

Mental Health Support

Parental Leave

Family Planning Benefits

Fertility Treatment Support

Stock Options

Company Equity

Conference Attendance Budget

Professional Development Budget

Birthdays?

Growth & Insights and Company News

Headcount

6 month growth

0%

1 year growth

2%

2 year growth

-2%
ConnectWeb
Sep 1st, 2026
News & articles.

News & articles. At ConnectWeb Connectweb has a team of editors and researchers collating the most relevant information to you and your industry. All Directories' publications and sites provide a wealth of information for research or marketing, and are used by public and corporate libraries, educational institutions, government departments, corporations and SMEs across the country. Access the latest company news and announcements distributed through Medianet. Medical, Health & Aged Care 01/09/2026 05:07 Hims arrives in Australia, bringing personalised care for men nationwide. Hims & Hers Pilot becomes Hims, bringing innovative, personalised care to help Australian men manage sexual health, weight loss, and hair loss SYDNEY-BUSINESS WIRE- Hims & Hers, the leading global health and wellness platform, today announced it is officially launching the Hims brand in Australia and bringing its personalised care platform to men nationwide. The entry follows Hims & Hers' acquisition of Eucalyptus earlier this year and begins with the rebrand of Pilot, Eucalyptus' men's health platform. Effective today, Pilot becomes Hims. Patients will maintain the treatment plans and provider relationships they rely on, now backed by a platform used and loved by millions of men worldwide. "For Australian men, digital care isn't just about convenience. It's about getting proactive help with the health issues that matter most to them, instead of waiting until it's unavoidable," said Gus Wood, General Manager of Australia at Hims & Hers. "Pilot has spent years earning that trust in Australia. Now we're building on that foundation with the leading global platform that sets the standard for men's health worldwide, so men can take charge of their health in the way that works for them, no matter where they live." The stakes are highest outside major cities. Nearly 30% of Australians live in regional and rural Australia, where distance from a GP or specialist can impact whether care happens at all. Where Pilot's care team was previously available 12 hours a day, Hims' in Australia extends that to 24/7 access, pairing proactive, comprehensive treatment with a Care Team patients can reach any hour, making quality care seamless and straightforward. "As a practising GP, I've seen how often men wait too long to act on something that was manageable if caught early," said Matt Vickers, FRACGP, MBBS, BMedSci, AICGG, Chief Medical Officer of Hims Australia. "This launch unites clinical rigour and convenience. Every treatment plan is grounded in the same evidence-based standards I'd want for my own patients, just delivered in a way that fits into a man's life instead of asking him to work around it. That's how we actually move the needle on men's health outcomes here, not just access to it." Patients will keep what they valued most from Pilot - Australian providers, local support, and continuity of care - while gaining access to a wider range of personalised care options built specifically for men's health. The launch also introduces combinations of care that bring together treatments that some patients previously received separately, including for premature ejaculation and cholesterol management. Patients will also gain access to new clinical pathways across multiple treatments and innovative formulations. Serving Australian patients well starts with local leadership and clinical expertise. Tim Doyle, former CEO of Eucalyptus and now Hims & Hers Senior Vice President of International, will oversee the Australian market alongside Gus Wood, General Manager of Australia. Dr. Matt Vickers, FRACGP, MBBS, BMedSci, AICGG, will serve as Chief Medical Officer of Hims Australia, ensuring care is grounded in local clinical standards from day one. About Hims & Hers Health, Inc. Hims & Hers is the leading global health and wellness platform on a mission to help the world feel great through the power of better health. Connectweb believe how you feel in your body and mind transforms how you show up in life. That's why Connectweb is building a future where nothing stands in the way of harnessing this power. Hims & Hers normalizes health & wellness challenges - and innovates on their solutions - to make feeling happy and healthy easy to achieve. No two people are the same, so the Company provides access to personalised care designed for results. For more information, please visit hims.com.au. Cautionary Statement Regarding Forward-Looking Statements This communication includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended and Section 21E of the Securities Exchange Act of 1934, as amended. These forward-looking statements can be identified by the use of forward-looking terminology, including the words "anticipates," "expects," "intends," "plans," "decides," "may," "will," "likely," "potential," "future," "over time," "coming," "hope," or "should," or, in each case, their negative or other variations or comparable terminology. There can be no assurance that actual results will not materially differ from expectations. Such statements include, but are not limited to, statements regarding Hims & Hers' expansion into Australia, its long-term financial targets, revenue expectations with respect to the Australian market, the transition from Pilot to Hims, including available offerings, and assumptions relating to the foregoing. These statements are based on management's current expectations, but actual results may differ materially due to various factors. Forward-looking statements are neither historical facts nor assurances of future performance. Instead, the forward-looking statements contained in this communication are based on its current expectations, assumptions and beliefs concerning future developments and their potential effects on Connectweb. Future developments affecting Connectweb may not be those that Connectweb has anticipated. These forward-looking statements involve a number of risks, uncertainties (some of which are beyond its control) and other assumptions that may cause actual results or performance to be materially different from those expressed or implied by these forward-looking statements. These risks and uncertainties include, but are not limited to, uncertainties relating to its ability to successfully integrate Eucalyptus and rebrand Eucalyptus' brands; uncertainties relating to the transition from Pilot to Hims, including its ability to retain Pilot's existing patients and provider relationships through the transition; its ability to achieve anticipated revenue, growth, and other benefits from its expansion into Australia and other international markets; competitive dynamics in the Australian men's health market; its ability to achieve its long-term financial targets; risks associated with international operations; changes in the application, interpretation and enforcement of healthcare, consumer protection, privacy or other laws and regulations applicable to its business; and other factors described in the Risk Factors and other sections of its most recently filed Quarterly Report on Form 10-Q, its most recently filed Annual Report on Form 10-K, and other current and periodic reports Connectweb file from time to time with the Securities and Exchange Commission. Should one or more of these risks or uncertainties materialize, or should any of its assumptions prove incorrect, actual results may vary in material respects from those projected in these forward-looking statements. The forward-looking statements contained in this communication are made only as of the date of this communication. Connectweb undertake no obligation (and expressly disclaim any obligation) to update or revise any forward-looking statements, or to update the reasons actual results could differ materially from those anticipated in the forward-looking statements, whether as a result of new information, future events or otherwise, except as may be required under applicable securities laws. By their nature, forward-looking statements involve risks and uncertainties because they relate to events and depend on circumstances that may or may not occur in the future. Connectweb caution you that forward-looking statements are not guarantees of future performance and that its actual results may differ materially from those made in or suggested by the forward-looking statements contained in this communication. Contact details: * Images - 26Q3_Pilot_Newsroom_1920x1008.jpg Download - Hims_Logo.jpg Download ConnectWeb. ConnectWeb is Australia's leading publisher of biographical data, directories and specialist newsletters. With ConnectWeb you gain access to its comprehensive database of contacts and companies in media, government and associations. Connect with Connectweb.

Schaeffer's Investment Research
Feb 20th, 2026
Geopolitical Tensions Resurface Amid Volatile Week

Geopolitical tensions resurface amid volatile week. The S&P 500 and Nasdaq boast healthy weekly gains. Assistant Editor Feb 20, 2026 at 2:09 PM Despite Tuesday's rough start, all three major indexes closed higher, the Nasdaq Composite (IXIC) snapping its four day-losing streak. Stocks held steady on Wednesday after receiving a boost from big tech gains, while the Federal Reserve's January meeting minutes held investor attention. On Thursday, the Dow Jones Industrial Average (DJI) and S&P 500 Index (SPX) both snapped three-day win streaks, while the Nasdaq also faced trouble; these losses slid right past traders as focus remained on geopolitical tensions and weekly jobless claims. The Nasdaq and S&P 500 are pacing for weekly gains, after the Supreme Court dismissed President Donald Trump's tariffs and lifted Wall Street's spirits. Stock movers this week. There were plenty of headlines for investors to unpack over the holiday-shortened week. Norwegian Cruise Line Holdings (NCLH) popped after reports that Elliott Investment Management has built an over 10% stake. In M&A news, Masimo (MASI) stock soared after reports that it will be acquired by Danaher (DHR) for $10 billion, while Hims & Hers Health (HIMS) announced its $1.15 billion acquisition of Australian digital health company Eucalyptus. In biotech news this week, the U.S. Food & Drug Administration (FDA) accepted Moderna's (MRNA) flu vaccine application for review, while Grail (GRAL) stock plummeted after the company's three-year cancer screening trial failed to meet its main goal. Meanwhile, Walmart's (WMT) disappointed earnings outlook contributed to pessimism on Thursday. Commodities, rare earths in focus. Rising oil prices were a highlight this week amid U.S.-Iran tensions, with options bulls targeting the United States Oil Fund (USO). Meanwhile, Devon Energy (DVN) tapped a 17-month high after strong fourth-quarter results, while Melius Research upgraded Chevon (CVX), citing exploration upside. Even further, gold mining name Newmont (NEM) continued to charge higher before its fourth-quarter report. On the flip side, rare earths stock MP Materials (MP) plummeted to a one-month low. As goes february. The final week of the month is jam packed with key earnings reports, delayed economic data, speeches from several Federal Reserve officials, and more. For now, Schaeffer's Senior V.P. of Research Todd Salamone says to keep your eye on these S&P 500 names, while Senior Quantitative Analyst Rocky White breaks down Wall Street's "fear gauge."

The Wall Street Journal
Feb 19th, 2026
Hims & Hers to Acquire Eucalyptus in $1.15 Billion Deal

Hims & Hers Health has agreed to acquire digital health company Eucalyptus in a deal valued at $1.15 billion in an effort to expand its geographic reach.

Investing.com
Feb 19th, 2026
Hims & Hers stock rises after agreement to acquire Eucalyptus

Hims & Hers stock rises after agreement to acquire Eucalyptus. ByInvesting.com Published 02/19/2026, 06:54 AM (C) Reuters. Investing.com - Hims & Hers Health, Inc. (NYSE:HIMS) stock rose 7.8% Thursday morning after the company announced it has entered into a definitive agreement to acquire Eucalyptus, an international digital health leader with operations in Australia, the UK, Germany, Japan, and Canada. The acquisition, valued at up to $1.15 billion USD, will accelerate Hims & Hers' global expansion strategy while preserving its financial flexibility. The company will pay approximately $240 million in cash upon closing, with the remaining consideration structured as deferred payments over 18 months and additional earnout payments tied to financial targets through early 2029. Eucalyptus, which operates consumer brands including Juniper and Pilot, has served more than 775,000 customers and currently maintains an annual revenue run-rate exceeding $450 million USD. The company has demonstrated triple-digit YoY revenue growth in each quarter of calendar year 2025 while operating near profitability. "Healthcare challenges are global, and so is the demand for simpler, transparent, and more personalized healthcare," said Andrew Dudum, founder and CEO of Hims & Hers. "With Eucalyptus, we will not only enter new markets, we will expand our ability to serve customers globally, trusting local experts to be a key part of how we transform healthcare into a customer-first, personalized industry." Following the acquisition's completion, Eucalyptus CEO Tim Doyle will become SVP of International at Hims & Hers, overseeing the company's international business. Eucalyptus' portfolio of brands will transition into Hims & Hers over time. The transaction is expected to close during the middle of calendar year 2026, subject to regulatory approvals and other customary closing conditions. Hims & Hers plans to finance most of the acquisition using existing cash and future operating cash flows from its U.S. operations. Which stock should you buy in your very next trade? AI computing powers are changing the stock market. Investing.com's ProPicks AI includes dozens of winning stock portfolios chosen by our advanced AI. Year to date, 2 out of 3 global portfolios are beating their benchmark indexes, with 88% in the green. Our flagship Tech Titans strategy doubled the S&P 500 within 18 months, including notable winners like Super Micro Computer (+185%) and AppLovin (+157%). Which stock will be the next to soar?

PR Newswire
Jul 28th, 2025
Amigo Partners with Eucalyptus to Scale AI-Powered Healthcare Delivery Across Global Telehealth Network

Amigo partners with Eucalyptus to scale ai-powered healthcare delivery across global telehealth network.